<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00900744</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-1373</org_study_id>
    <secondary_id>IF#1248430</secondary_id>
    <secondary_id>HSM10-00403</secondary_id>
    <nct_id>NCT00900744</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6</brief_title>
  <official_title>A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to examine endoxifen and 4-OH-Tam as a function of the tamoxifen dose&#xD;
      in patients with a genetic CYP2D6 polymorphism. The investigators also plan to investigate&#xD;
      other genetic variations in the metabolism of tamoxifen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endocrine therapy has proven to be an extremely effective therapy in breast cancer. For women&#xD;
      with hormone-receptor-positive tumors, tamoxifen given for as little as two years results in&#xD;
      a statistically significant recurrence and survival benefit. The benefits increase as the&#xD;
      duration of treatment increase, up to 5 years, so that among women treated for five years,&#xD;
      tamoxifen can result in up to a 46 percent annual reduction in the recurrence rate and up to&#xD;
      a 28 percent annual reduction in the death rate. This means that about half of the&#xD;
      recurrences and more than one fourth of the deaths each year are prevented by tamoxifen&#xD;
      treatment. However, despite initial successful responses, many patients on tamoxifen relapse&#xD;
      and die from progressive disease. Consequently, tamoxifen resistance remains a major clinical&#xD;
      problem in the management of breast cancer.&#xD;
&#xD;
      Tamoxifen is metabolized by cytochrome P450 2D6 (CYP2D6) to the more potent metabolites&#xD;
      4-hydroxy-tamoxifen (4-OH-TAM) and 4-hydroxy-N-desmethyltamoxifen (endoxifen). Variations in&#xD;
      the metabolic capacity of this enzyme have shown to be an independent predictor of breast&#xD;
      cancer relapse and death. To date, studies have not correlated tamoxifen doses to CYP2D6&#xD;
      genotype status or associated tamoxifen doses to endoxifen and 4-OH-tamoxifen.&#xD;
&#xD;
      The investigators plan to examine endoxifen and 4-OH-Tam as a function of the tamoxifen dose&#xD;
      in patients with a genetic CYP2D6 polymorphism. The investigators also plan to investigate&#xD;
      other genetic variations in the metabolism of tamoxifen. The possible identification of gene&#xD;
      variants that alter tamoxifen's metabolism may improve initial dose selection and therefore&#xD;
      optimize treatment outcome in the future.&#xD;
&#xD;
      In addition to examining polymorphisms in CYP2D6, other genes will be examine that may&#xD;
      influence the metabolism of medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Specific human 2D6 variants measurement(s) or observation(s)</measure>
    <time_frame>every two weeks</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">121</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <description>20mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>20 mg daily</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>NolvadexÂ®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with a genetic CYP2D6 polymorphism&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women taking tamoxifen 20mg a day&#xD;
&#xD;
          -  Tamoxifen use for &gt; 90 days.&#xD;
&#xD;
          -  Use an accepted barrier form of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients are excluded if they are pregnant or lactating; if pre- menopausal, the&#xD;
             patient will have a documented negative pregnancy test and use an accepted barrier&#xD;
             form of contraception.&#xD;
&#xD;
          -  Patients are excluded if they have a medical history of Hepatitis B. Hepatitis C or&#xD;
             HIV&#xD;
&#xD;
          -  Patients are excluded if they use Tobacco&#xD;
&#xD;
          -  Patients are excluded if they have a medical history of hereditary hemochromatosis&#xD;
&#xD;
          -  Patients are excluded if they have elevated AST (SGOT), ALT (SGPT), Bilirubin or&#xD;
             Alkaline Phosphate&#xD;
&#xD;
             o Defined as greater than 2 1/2 times the upper limit of normal&#xD;
&#xD;
          -  Patients are excluded if they are being treated with chemotherapy&#xD;
&#xD;
          -  Patients are excluded if they are taking any of the following oral medications, as&#xD;
             they are potent CYP2D6 inhibitors:&#xD;
&#xD;
               -  Fluoxetine (Prozac)&#xD;
&#xD;
               -  Miconazole (Monistat)&#xD;
&#xD;
               -  Paroxetine (Paxil)&#xD;
&#xD;
               -  Quinidine&#xD;
&#xD;
               -  Ritonavir (Norvir)&#xD;
&#xD;
               -  Atorvastatin (Lipitor)&#xD;
&#xD;
               -  Carvedilol (Coreg)&#xD;
&#xD;
               -  Clarithromycin (Biaxin)&#xD;
&#xD;
               -  Dipyridamole (Persantine)&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Grapefruit Juice&#xD;
&#xD;
               -  Itraconazole (Sporanox)&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Mefloquine&#xD;
&#xD;
               -  Nelfinavir (Viracept)&#xD;
&#xD;
               -  Nicardipine (Cardene)&#xD;
&#xD;
               -  Nilotinib&#xD;
&#xD;
               -  Propranolol (Inderal)&#xD;
&#xD;
               -  Ranolazine (Ranexa)&#xD;
&#xD;
               -  Saquinavir ( Invirase)&#xD;
&#xD;
               -  Verapamil Covera-HS&#xD;
&#xD;
               -  Warfarin (Coumadin)&#xD;
&#xD;
               -  Chlorpromazine (Thorazine)&#xD;
&#xD;
               -  Cinacalcet (Sensipar)&#xD;
&#xD;
               -  Delavirdine (Rescriptor)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Raptis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2009</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tamoxifen</keyword>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

